Business / Finance

RSS

Norgine signs exclusive licensing agreement with Innovacell for ICEF15

Norgine B.V. and Innovacell today announced they have entered into an exclusive licensing agreement for Europe, SADAC and MENA for ICEF15. Innovacell and Norgine will co-develop ICEF15 and Norgine will commercialise the product. The start of the ICEF15 phase IIb clinical trial is imminent and it is anticipated that the first patient will be dosed in Q1 2014.

17 Dec 2013

Medical Daily announces marketing and distribution partnership with UBM Medica US

Medical Daily announced today a unique marketing and distribution partnership with UBM Medica US. Medical Daily is a source of breaking health news, scientific trends and innovations.

16 Dec 2013

MicroBiome Therapeutics announces completion of $1.3M bridge financing

MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.

16 Dec 2013

NYSE publicly traded industry selects EPGL's advanced technologies for development

EP Global Communications, Inc., makes the following announcement: In a first for the company, one of EPGL's advanced technologies has been selected by a multi-billion dollar, NYSE publicly traded industry leader for development and integration into new products.

16 Dec 2013

NHS Alliance collaborates with ITN Productions to launch NHS Alliance TV 2013

The NHS Alliance and ITN Productions have joined forces to release NHS Alliance TV 2013, an in-depth, sector-focussed news programme for healthcare professionals. Hosted by Natasha Kaplinsky from ITN's London studios, NHS Alliance TV was launched to over 500 industry leaders at the NHS Alliance Conference, and is now available on ITN's dedicated Healthcare News website.

16 Dec 2013

RT Oncology and Express Scripts enter into pharmaceutical drug distribution agreement

RT Oncology Services Corporation ("RainTree"), the nation's leading community oncology alliance, and Express Scripts (NASDAQ: ESRX), the nation's leading pharmacy benefit manager, today announced that they have entered into an exclusive, three-year pharmaceutical drug distribution agreement.

16 Dec 2013

Savient gets bankruptcy court approval to sell all assets to Crealta

Savient Pharmaceuticals, Inc. announced that it has received approval from the U.S. Bankruptcy Court for the District of Delaware to sell substantially all of the assets of Savient, including all KRYSTEXXA assets, to Crealta Pharmaceuticals LLC.

13 Dec 2013

Centene updates 2013 financial guidance, announces financial guidance for 2014 fiscal year

Centene Corporation announced today its 2014 financial guidance. Premium and service revenues are expected to be $13.5 billion to $14.0 billion, representing growth of 29%.

13 Dec 2013

Retrophin to acquire privately-held company, Kyalin Biosciences

Retrophin, Inc. today announced that it will acquire privately-held Kyalin Biosciences, Inc., an early-stage company based in San Diego, CA, that is developing therapies targeting the core symptoms of autism and related conditions.

12 Dec 2013

Mazor Robotics to be included in TASE Top 75 Index and Top 100 Index from Dec 15, 2013

Mazor Robotics Ltd., the developer of Renaissance™, an innovative surgical guidance system and its complementary products, announced today that it will be included in both the Tel Aviv Stock Exchange (TASE) Top 75 Index (TA-75) and Top 100 Index (TA-100), effective December 15, 2013.

12 Dec 2013

Eastern Technologies merges with Global Resources International

Generational Equity, a leading mergers and acquisitions advisor for privately-held, middle-market businesses, is pleased to announce the merger of its client, Eastern Technologies, Inc., headquartered in Ashford, Alabama, with Global Resources International, Inc., headquartered in Flowery Branch, Georgia.

12 Dec 2013

Senhwa Biosciences raises additional $17 million USD in Series B financing

Senhwa Biosciences, Inc. has raised an additional $17 million USD in a Series B financing to drive its anticancer agents through critical clinical trials, the company announced today.

12 Dec 2013

ZEISS reports record revenue in fiscal year 2012/13

ZEISS has brought fiscal year 2012/13 to a successful conclusion (reporting date: 30 September 2013) with a new record high in revenue. The company generated revenue totaling EUR 4.190 billion (prior year: EUR 4.163 billion) and earnings (EBIT) of EUR 335 million (prior year: EUR 420 million).

12 Dec 2013

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

Synthetic Biologics, Inc., a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share.

12 Dec 2013

Endo Finance prices $700 million aggregate principal amount of 5.75% senior unsecured notes

Endo Health Solutions ("Endo") today announced that Endo Finance Co., its wholly-owned subsidiary ("Endo Finance"), priced $700 million aggregate principal amount of 5.75% senior unsecured notes due January 2022 at an issue price of $1,000 per $1,000 principal amount (the "notes") in connection with its previously announced private offering.

12 Dec 2013

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

Avinger closes significant funding round to initiate clinical trial on peripheral atherectomy catheter

Avinger, Inc. producer of therapeutic devices incorporating intravascular imaging and pioneer of the lumivascular approach to treating vascular disease, announced today the closing of a significant funding round.

12 Dec 2013

Crealta to acquire all assets of Savient Pharmaceuticals

Savient Pharmaceuticals, Inc. ("Savient") announced that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million.

11 Dec 2013

Pfizer, Octapharma AG to market investigational agent for urgent reversal of vitamin K antagonist

...

11 Dec 2013

Vestiage selects ROI Media for direct to consumer marketing campaign

Vestiage, Inc., a publicly traded healthy aging lifestyle company focused on science-based premium branded highly potent cosmeceuticals and nutraceuticals, announced today that it has engaged ROI Media to orchestrate its direct to consumer marketing campaign.

11 Dec 2013

Business / Finance

Norgine signs exclusive licensing agreement with Innovacell for ICEF15

Medical Daily announces marketing and distribution partnership with UBM Medica US

MicroBiome Therapeutics announces completion of $1.3M bridge financing

NYSE publicly traded industry selects EPGL's advanced technologies for development

NHS Alliance collaborates with ITN Productions to launch NHS Alliance TV 2013

RT Oncology and Express Scripts enter into pharmaceutical drug distribution agreement

Savient gets bankruptcy court approval to sell all assets to Crealta

Centene updates 2013 financial guidance, announces financial guidance for 2014 fiscal year

Retrophin to acquire privately-held company, Kyalin Biosciences

Mazor Robotics to be included in TASE Top 75 Index and Top 100 Index from Dec 15, 2013

Eastern Technologies merges with Global Resources International

Senhwa Biosciences raises additional $17 million USD in Series B financing

ZEISS reports record revenue in fiscal year 2012/13

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

Endo Finance prices $700 million aggregate principal amount of 5.75% senior unsecured notes

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Avinger closes significant funding round to initiate clinical trial on peripheral atherectomy catheter

Crealta to acquire all assets of Savient Pharmaceuticals

Pfizer, Octapharma AG to market investigational agent for urgent reversal of vitamin K antagonist

Vestiage selects ROI Media for direct to consumer marketing campaign

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News